CTC immune escape mediated by PD-L1

被引:37
|
作者
Wang, Xuefei
Sun, Qiang
Liu, Qiaofei
Wang, Changjun
Yao, Ru
Wang, Yimin
机构
[1] Chinese Acad Med Sci, Breast Surg Dept, Beijing, Peoples R China
[2] Peking Union Med Coll, Peking Union Med Coll & Hosp, Beijing, Peoples R China
[3] Shanxi Prov Peoples Hosp, Xian, Shaanxi, Peoples R China
关键词
BREAST-CANCER; CELLS; SUPPRESSION;
D O I
10.1016/j.mehy.2016.05.022
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Breast cancer is the most common malignant tumor in women around the world. Most breast cancer related deaths are from CTC (circulating tumor cells) metastasis. CTC is associated with the breast cancer patients' prognosis. But recently, circulating clusters were found and its metastasis and tumor formation ability is 23-50 times as CTC. However, its mechanism has not been clarified. These days, researchers have successfully completed CTC cluster separation, CTC cell culture, and PD-L1 was found to be related with histological grading of tumor. Meanwhile, the high expression of PD-L1 in CTC surface has also been reported. Since PD-L1 can mediate Treg to play the role of immunosuppression, we propose that CTC with positive PD-L1 is easier to connect PD-L1, immune cells (Treg regulatory T cells, MDSC bone marrow inhibitory cells) and CM cytokines etc. On one hand, Treg cells can protect CTC from being attacked by the immune system through the immunosuppression, on the other hand, they can weaken CTL killing ability and trigger more MDSC. Finally, CTC formed the metastatic lesion. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:138 / 139
页数:2
相关论文
共 50 条
  • [21] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [22] Expression of the Extracellular Domain of Mouse PD-L1 and Production of Antibodies to PD-L1
    Goryunova, M. S.
    Ryazantsev, D. Yu.
    Petrova, E. E.
    Kostenko, V. V.
    Makarova, A. O.
    Kholodenko, R. V.
    Ryabukhina, E. V.
    Kalinovsky, D. V.
    Kotsareva, O. D.
    Svirshchevskaya, E. V.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2024, 50 (06) : 2644 - 2656
  • [23] Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1/PD-L1 Pathway
    Nakamori, Yuki
    Park, Eun Jeong
    Shimaoka, Motomu
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [24] Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion
    Miller, Tim J.
    Mccoy, Melanie J.
    Hemmings, Christine
    Iacopetta, Barry
    Platell, Cameron F.
    ONCOLOGY LETTERS, 2018, 16 (05) : 5761 - 5768
  • [25] Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression
    Zhang, Hong
    Xia, Yuhui
    Wang, Fang
    Luo, Min
    Yang, Ke
    Liang, Shaobo
    An, Sainan
    Wu, Shaocong
    Yang, Chuan
    Chen, Da
    Xu, Meng
    Cai, Muyan
    To, Kenneth K. W.
    Fu, Liwu
    ADVANCED SCIENCE, 2021, 8 (10)
  • [26] Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
    Prestipino, Alessandro
    Emhardt, Alica J.
    Aumann, Konrad
    O'Sullivan, David
    Gorantla, Sivahari P.
    Duquesne, Sandra
    Melchinger, Wolfgang
    Braun, Lukas
    Vuckovic, Slavica
    Boerries, Melanie
    Busch, Hauke
    Halbach, Sebastian
    Pennisi, Sandra
    Poggio, Teresa
    Apostolova, Petya
    Veratti, Pia
    Hettich, Michael
    Niedermann, Gabriele
    Bartholomae, Mark
    Shoumariyeh, Khalid
    Jutzi, Jonas S.
    Wehrle, Julius
    Dierks, Christine
    Becker, Heiko
    Schmitt-Graeff, Annette
    Follo, Marie
    Pfeifer, Dietmar
    Rohr, Jan
    Fuchs, Sebastian
    Ehl, Stephan
    Hartl, Frederike A.
    Minguet, Susana
    Miething, Cornelius
    Heidel, Florian H.
    Kroeger, Nicolaus
    Triviai, Ioanna
    Brummer, Tilman
    Finke, Jurgen
    Illert, Anna L.
    Ruggiero, Eliana
    Bonini, Chiara
    Duyster, Justus
    Pahl, Heike L.
    Lane, Steven W.
    Hill, Geoffrey R.
    Blazar, Bruce R.
    von Bubnoff, Nikolas
    Pearce, Erika L.
    Zeiser, Robert
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (429)
  • [27] Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
    Liu, Jingwei
    Li, Hao
    Sun, Liping
    Yuan, Yuan
    Xing, Chengzhong
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [28] Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma
    Han, Seunggu J.
    Reis, Gerald
    Kohanbash, Gary
    Shrivastav, Shruti
    Magill, Stephen T.
    Molinaro, Annette M.
    McDermott, Michael W.
    Theodosopoulos, Philip V.
    Aghi, Manish K.
    Berger, Mitchel S.
    Butowski, Nicholas A.
    Barani, Igor
    Phillips, Joanna J.
    Perry, Arie
    Okada, Hideho
    JOURNAL OF NEURO-ONCOLOGY, 2016, 130 (03) : 543 - 552
  • [29] Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
    Thuru, Xavier
    Magnez, Romain
    El-Bouazzati, Hassiba
    Vergoten, Gerard
    Quesnel, Bruno
    Bailly, Christian
    CANCERS, 2022, 14 (14)
  • [30] Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
    Koirala, Pratistha
    Roth, Michael E.
    Gill, Jonathan
    Piperdi, Sajida
    Chinai, Jordan M.
    Geller, David S.
    Hoang, Bang H.
    Park, Amy
    Fremed, Michael A.
    Zang, Xingxing
    Gorlick, Richard
    SCIENTIFIC REPORTS, 2016, 6